Circulating cell-free DNA (cfDNA) in patients with medullary thyroid carcinoma is characterized by specific fragmentation and methylation changes with diagnostic value

Circulating cell-free DNA (cfDNA) in patients with medullary thyroid carcinoma is characterized by specific fragmentation and methylation changes with diagnostic value

Abstract Medullary Thyroid Carcinoma (MTC) is a rare neuroendocrine tumour whose diagnosis includes evaluating calcitonin serum levels, which can present fluctuations unrelated to MTC. Here, we investigated circulating DNA fragmentation and methylation changes as potential biomarkers using ddPCR on...

Full description

Bibliographic Details
Main Authors:	Anna Citarella, Zein Mersini Besharat, Sofia Trocchianesi, Tanja Milena Autilio, Antonella Verrienti, Giuseppina Catanzaro, Elena Splendiani, Zaira Spinello, Silvia Cantara, Patrizia Zavattari, Eleonora Loi, Cristina Romei, Raffaele Ciampi, Luciano Pezzullo, Maria Grazia Castagna, Antonio Angeloni, Rosella Elisei, Cosimo Durante, Agnese Po, Elisabetta Ferretti
Format:	Article
Language:	English
Published:	BMC 2023-09-01
Series:	Biomarker Research
Subjects:	Medullary thyroid carcinoma Rare tumour Cell-free DNA Circulating DNA methylation Circulating DNA fragmentation Circulating biomarker
Online Access:	https://doi.org/10.1186/s40364-023-00522-4

Similar Items

cfDNA Sequencing: Technological Approaches and Bioinformatic Issues
by: Elodie Bohers, et al.
Published: (2021-06-01)

Detection of EGFR Mutations in Plasma cfDNA and Paired CTCs of NSCLC Patients before and after Osimertinib Therapy Using Crystal Digital PCR
by: Aliki Ntzifa, et al.
Published: (2021-05-01)

DNA repair deficiency as circulating biomarker in prostate cancer
by: Martina Catalano, et al.
Published: (2023-01-01)

From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real‐world setting
by: Steven P. Rowe, et al.
Published: (2018-10-01)

Circulating cell-free DNA and circulating tumor cells, the “liquid biopsies” in ovarian cancer
by: Xianliang Cheng, et al.
Published: (2017-11-01)

Cell-Free Circulating (Tumor) DNA before Surgery as a Prognostic Factor in Non-Metastatic Colorectal Cancer: A Systematic Review
by: Suzanna J. Schraa, et al.
Published: (2022-04-01)

Putative Origins of Cell-Free DNA in Humans: A Review of Active and Passive Nucleic Acid Release Mechanisms
by: Stefan Grabuschnig, et al.
Published: (2020-10-01)

Molecular and cellular pathophysiology of circulating cardiomyocyte-specific cell free DNA (cfDNA): Biomarkers of heart failure and potential therapeutic targets
by: Abhi Dutta, et al.
Published: (2023-05-01)

Circulating Tumor DNA (ctDNA) Clearance May Predict Treatment Response in Neoadjuvant Colorectal Cancer Management
by: Britney Niemann, et al.
Published: (2024-03-01)

Liquid Biopsy for Cancer: Circulating Tumor Cells, Circulating Free DNA or Exosomes?
by: Wei Zhang, et al.
Published: (2017-02-01)

DNA Methylation in Circulating Tumour DNA as a Biomarker for Cancer
by: Ruth E Board, et al.
Published: (2007-01-01)

Early circulating tumor DNA dynamics at the commencement of curative-intent radiotherapy or chemoradiotherapy for NSCLC
by: Michael MacManus, et al.
Published: (2023-11-01)

Monitoring of circulating tumor DNA and its aberrant methylation in the surveillance of surgical lung Cancer patients: protocol for a prospective observational study
by: Guannan Kang, et al.
Published: (2019-06-01)

Concordance between cancer gene alterations in tumor and circulating tumor DNA correlates with poor survival in a real‐world precision‐medicine population
by: Shai Rosenberg, et al.
Published: (2023-09-01)

A Systematic Review of miRNA and cfDNA as Potential Biomarkers for Liquid Biopsy in Myocarditis and Inflammatory Dilated Cardiomyopathy
by: Piotr Lewandowski, et al.
Published: (2022-10-01)

Circulating free DNA in hypertensive patients with high cardiovascular risk
by: E. A. Trofimova, et al.
Published: (2022-05-01)

Impact of Circulating Cell-Free DNA (cfDNA) as a Biomarker of the Development and Evolution of Periodontitis
by: Gaia Viglianisi, et al.
Published: (2023-06-01)

High‐throughput isolation of circulating tumor DNA: a comparison of automated platforms
by: Lisanne F. vanDessel, et al.
Published: (2019-02-01)

Plasma cfDNA methylation markers for the detection and prognosis of ovarian cancer
by: Leilei Liang, et al.
Published: (2022-09-01)

Cell-free circulating tumor DNA in cancer
by: Zhen Qin, et al.
Published: (2016-04-01)

The rising tide of cell-free DNA profiling: from snapshot to temporal genome analysis
by: Bronkhorst Abel Jacobus, et al.
Published: (2022-08-01)

Longitudinal Study of Circulating Biomarkers in Patients with Resectable Pancreatic Ductal Adenocarcinoma
by: Pablo J. Dopico, et al.
Published: (2022-03-01)

New Perspectives on the Importance of Cell-Free DNA Biology
by: Abel J. Bronkhorst, et al.
Published: (2022-09-01)

Prognostic implications of circulating Epstein–Barr virus DNA for extranodal natural killer/T-cell lymphoma, nasal type: a meta-analysis
by: Chen RW, et al.
Published: (2018-07-01)

Liquid Biopsy Using Cell-Free or Circulating Tumor DNA in the Management of Hepatocellular CarcinomaSummary
by: Xueying Lyu, et al.
Published: (2022-01-01)

Circulating tumour DNA as biomarker for rectal cancer: A systematic review and meta-analyses
by: Jan M. van Rees, et al.
Published: (2023-01-01)

Performative Circulations: On Flows and Stops in Forensic DNA Practices
by: Amade M’charek
Published: (2017-01-01)

The role of circulating tumor DNA in patients with colon cancer
by: M. Yu. Fedyanin, et al.
Published: (2016-10-01)

Methylated APC and GSTP1 genes in serum DNA correlate with the presence of circulating blood tumor cells and are associated with a more aggressive and advanced breast cancer disease
by: Matuschek C, et al.
Published: (2010-07-01)

Evaluation of the cell-free DNA integrity index as a liquid biopsy marker to differentiate hepatocellular carcinoma from chronic liver disease
by: Sonu Kumar, et al.
Published: (2022-11-01)

Molecular Profiling of Circulating Tumour Cells and Circulating Tumour DNA: Complementary Insights from a Single Blood Sample Utilising the Parsortix<sup>®</sup> System
by: Gabrielle Wishart, et al.
Published: (2024-01-01)

Methylation of cell-free circulating DNA in the diagnosis of cancer
by: Goli eSamimi, et al.
Published: (2015-04-01)

Circulating tumor DNA in cancer diagnosis, monitoring, and prognosis
by: Sudeepto Saha, et al.
Published: (2022-02-01)

A New Horizon of Liquid Biopsy in Thymic Epithelial Tumors: The Potential Utility of Circulating Cell-Free DNA
by: Margaret Ottaviano, et al.
Published: (2021-02-01)

Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An Update
by: Joanna Kapeleris, et al.
Published: (2022-03-01)

Prediction of the treatment response in ovarian cancer: a ctDNA approach
by: Mina Sharbatoghli, et al.
Published: (2020-10-01)

Diagnostic value of circulating cell-free DNA levels for hepatocellular carcinoma
by: Linlin Yan, et al.
Published: (2018-02-01)

Clinical applications of liquid biopsy as prognostic and predictive biomarkers in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA
by: Jie Li, et al.
Published: (2018-09-01)

Advances in Clinical Application of ctDNA in Tumor Detection, Screening, Prognosis and Treatment
by: LIU Yong
Published: (2020-08-01)

Circulating Tumour DNA as Biomarker for Colorectal Liver Metastases: A Systematic Review and Meta-Analysis
by: Lissa Wullaert, et al.
Published: (2023-10-01)